Press Releases


Latest News


Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
Jun 9, 2014 | General Releases

United States Patent Issued To Adamas Pharmaceuticals
Jun 9, 2014 | General Releases

Adamas Pharmaceuticals Announces Data Update At The International Congress Of Parkinson's Disease And Movement Disorders
May 29, 2014 | General Releases

Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
May 20, 2014 | General Releases

Adamas Reports First Quarter 2014 Financial Results
May 13, 2014 | Financial Releases

Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting
Apr 30, 2014 | General Releases

Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting
Apr 23, 2014 | General Releases

Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering
Apr 15, 2014 | General Releases

Adamas Pharmaceuticals Announces Pricing of its Initial Public Offering
Apr 9, 2014 | General Releases

Forest Laboratories and Adamas Pharmaceuticals Announce Forest's Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer's Disease
Mar 4, 2014 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10